Skip to content
It’s been a thrilling year of ups and downs for Inovio (NASDAQ:INO). INO stock rocketed as much as 1,000% earlier this year following news that Inovio had a leading candidate in the race for a novel coronavirus vaccine. Things have gotten more complicated since summer, though.
Source: Ascannio / Shutterstock.com The government left Inovio out of its multi-billion dollar Operation Warp Speed to hurry along vaccine development. Inovio’s small trial size — compared to rivals — raised doubts about the quality of its research.
And repeated advances in other Covid-19 vaccine programs made it appear that Inovio was falling behind. Still, Inovio investors had hope. As recently as two weeks ago, INO stock popped 50% on a favorable corporate update.InvestorPlace - Stock Market News, Stock Advice & Trading Tips
On Monday, however, everything changed. The Food and Drug Administration (FDA) hit Inovio’s Covid-19 vaccine with a dreaded partial clinical hold. The 7 Top Robinhood...
What with all the trials under way to produce a vaccine for the novel coronavirus these days, trials of another kind have popped up, enough to make investors ill. Shares in Inovio Pharmaceuticals (NASDAQ:INO) cratered by a third in just 48 hours, beginning on Monday Sept. 28, after news that the FDA halted a planned Phase 2/3 clinical trial of its Covid-19 vaccine candidate INO-4800. Not long before that, AstraZeneca (NYSE:AZN) suspended a trial when a previously healthy 37-year-old woman was hospitalized on Sept. 5 after receiving her second dose of a vaccine in clinical trial. The question is whether maladies such as these might infect entrants such as iBio (NYSEAMERICAN:IBIO) and IBIO stock.
Source: Shutterstock Before you blurt out an answer, let’s take a second to appreciate just how complicated the vaccine milieu is at this point. Behold:
At least 15 companies are vying to cross the finish line first in the vaccine...
(Bloomberg) -- U.S. President Donald Trump said early Friday that he has tested positive for coronavirus along with his wife and one of his closest aides, throwing an already volatile campaign into deeper disarray just one month before the election.“Tonight, @FLOTUS and I tested positive for COVID-19. We will begin our quarantine and recovery process immediately. We will get through this TOGETHER!,” the president said on Twitter, hours after Bloomberg News reported that the adviser, Hope Hicks, had fallen ill with the virus.The election campaign against Democrat Joe Biden has focused heavily on Trump’s handling of the coronavirus, which has already killed more than 200,000 Americans and deepened inequalities. Biden and others have criticized Trump’s response as slow off the mark and ineffective.Biden was expected to be tested for the virus on Friday, according to a person familiar with his campaign’s plans. The two shared a stage Tuesday at the presidential...
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is......
Today is shaping up negative for Nikola Corporation (NASDAQ:NKLA) shareholders, with the analysts delivering a......
When I last wrote about Canopy Growth (NYSE:CGC) in mid-June, the Canadian cannabis company had just announced a loss of 1.3 billion Canadian dollars ($952.1 million). As a result, chief executive officer David Klein introduced a strategy reset that would create a renewed focus. No longer would it be all things to all people. I thought this would be good for CGC stock.
Source: Shutterstock In the three months since my June article, CGC stock has lost almost 14% through Sept. 28. Patient investors needn’t worry. Here’s why.InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Until a few days ago, it had traded in a tight range between $16 and $18. Then Acreage Holdings (OTCMKTS:ACRGF) announced its amended arrangement for Canopy to purchase the company once the U.S. federal government legalizes cannabis.
Essentially, it allows Canopy to buy all of the newly created Class E subordinate voting shares at a fixed rate...
Disney (NYSE:DIS) has not a good year so far. In 2020 DIS stock is down 13%. The media giant has recently announced it is laying off 28,000 U.S.-based employees in its theme-park division.
Source: nikkimeel / Shutterstock.com These theme parks are in California and Florida, two states where the pandemic has significantly disrupted lives. According to the “Theme Index and Museum Index: The Global Attractions Attendance Report,” in 2019 Disney venues were the most visited U.S. theme parks. Global operations also had a similar success.
“Measures used to limit the spread of COVID-19 … are expected to have particularly severe impacts on… theme parks,” Recent research by Todd Gabe of University of Maine highlights. “These capacity constraints will lower annual attendance figures and the admission fees collected by theme parks, as well as impact the surrounding regions where major theme parks are located.”InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Disney has been...
